Biogen Inc (NASDAQ:BIIB) price on current trading day, rose 2.40% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $123.98.
A look at the stock’s price movement, the level at last check in today’s session was $121.08, moving within a range at $118.2 and $125.34. The beta value (5-Year monthly) was 0.057 while the PE ratio in trailing twelve months stood at 11.09. Turning to its 52-week performance, $238.00 and $110.04 were the 52-week high and 52-week low respectively. Overall, BIIB moved -6.10% over the past month.
Biogen Inc’s market cap currently stands at around $18.17 billion, with investors looking forward to this quarter’s earnings report slated for on 2025-Feb-11.
Analysts have a consensus estimate of 2.32B for the company’s revenue for the quarter, with a low and high estimate of 2.25B and 2.43B respectively. The average forecast suggests down to a -5.80% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 9.18B, representing a -5.16% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that BIIB is a 50% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
32 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 5 analyst(s) rate the stock as a Hold, 27 recommend BIIB as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
BIIB’s current price about 4.08% and -6.33% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 49.94, while 7-day volatility ratio is 2.48% and 4.06% in the 30-day chart. Further, Biogen Inc (BIIB) has a beta value of 0.12, and an average true range (ATR) of 4.44. Analysts have given the company’s stock an average 52-week price target of $180, forecast between a low of $118 and high of $300. Looking at the price targets, the low is 4.82% off recent price level in today’s trading while to achieve the yearly target high, it has to move -141.97%. Nonetheless, investors will most likely welcome a -45.18% jump to $180 which is the analysts’ median price.
If we refocus on Biogen Inc (NASDAQ:BIIB), historical trading data shows that trading volumes averaged 1.48 over the past 10 days and 1.74 million over the past 3 months. The company’s latest data on shares outstanding shows there are 145.80 million shares.
The 0.51% of Biogen Inc’s shares are in the hands of company insiders while institutional holders own 91.51% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 3.45 million on 2025-04-15, giving us a short ratio of 1.87. The data shows that as of 2025-04-15 short interest in Biogen Inc (BIIB) stood at 265.00002 of shares outstanding, with shares short rising to 3.31 million registered in 2025-03-14. Current price change has pushed the stock -18.92% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the BIIB stock continues to rise going into the next quarter.
